By Fineline Cube 
China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for the first half of 2025. The company generated RMB 5,953.1 million in revenue, a 50.6 % year‑on‑year increase, and posted a net profit of RMB 834.3 million, a sharp turnaround from the previous period’s deficit.
Financial Highlights
| Metric | H1 2025 | YoY % Change |
|---|---|---|
| Total Revenue | RMB 5,953.1 m | +50.6 % |
| Product Revenue | RMB 5,233.8 m | +37.3 % |
| License Fee Income | RMB 665.6 m | +— (Roche upfront) |
| Net Profit | RMB 834.3 m | — (from loss) |
Product Portfolio Expansion
Innovent’s product line grew to 16 items, adding five new launches during the reporting period:
- Oncology
- DOVBLERON (taletrectinib)
- limertinib (EGFR‑TKI)
- Jaypirca (pirtobrutinib)
- General Biomedicine
- SYCUME (teprotumumab N01)
- mazdutide (GLP‑1/GLP‑G dual agonist)
Two investigational candidates are now under NDA review:
- IBI112 (picankibart, IL‑23p19 antibody) – moderate‑to‑severe plaque psoriasis
- IBI310 (ipilimumab N01) + TYVYT (sintilimab) – neoadjuvant therapy for MSI‑H/dMMR colon cancer
Strategic Licensing and Partnerships
- Roche Collaboration – Generated a significant upfront fee, boosting license‑income and reinforcing Innovent’s position in the oncology arena.
- Pipeline Momentum – The addition of GLP‑1/GLP‑G dual‑agonist mazdutide signals a strategic pivot toward metabolic disease, complementing the company’s oncology strength.
Outlook
With a solid cash position and a growing product slate, Innovent is poised to sustain its revenue momentum, deepen its oncology portfolio, and accelerate the commercialization of its GLP‑1‑based therapy.-Fineline Info & Tech